Comparison of the Effectiveness of Pirfenidone and Nintedanib in Patients with Advanced Stage Idiopathic Pulmonary Fibrosis

Güliz Değirmenci; Celal Satici; Damla Azaklı Yazıcı; Nazım Çetinkaya; Umut Erdem; Barış Demirkol; Ayşegül Erinç

doi:10.36141/svdld.v42i4.16849

Authors

Güliz Değirmenci Yedikule Chest Disease and Chest Surgery Research and Treatment Hospital, Department of Chest Disease https://orcid.org/0009-0002-4372-4247
Celal Satici Yedikule Chest Disease and Chest Surgery Research and Treatment Hospital, Department of Chest Disease https://orcid.org/0000-0002-5457-9551
Damla Azaklı Yazıcı Basaksehir Cam and Sakura City Hospital, Department of Chest Disease https://orcid.org/0000-0002-5850-2076
Nazım Çetinkaya Sisli Hamidiye Etfal Research and Treatment Hospital, Department of Radiology
Umut Erdem Sisli Hamidiye Etfal Research and Treatment Hospital, Department of Radiology
Barış Demirkol Basaksehir Cam and Sakura City Hospital, Department of Chest Disease
Ayşegül Erinç Yedikule Chest Disease and Chest Surgery Research and Treatment Hospital, Department of Chest Disease

Keywords:

Idiopathic Pulmonary Fibrosis, Advanced stage, Nintedanib, Pirfenidone, Mortality, Antifibrotic therapy

Abstract

Background and aim: Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease with high mortality, especially in advanced stages, defined as forced vital capacity (FVC) ≤50% and/or diffusing capacity of the lungs for carbon monoxide (DLCO) ≤30% of predicted values. While antifibrotic therapies, such as nintedanib and pirfenidone, are effective in mild to moderate IPF, their efficacy in advanced-stage IPF remains unclear due to the exclusion of these patients from major clinical trials. This study aimed to compare the effectiveness of nintedanib and pirfenidone on mortality and to identify predictors of mortality in patients with advanced-stage IPF.

Methods: This retrospective cohort study included 198 advanced-stage IPF patients treated with nintedanib (n=91) or pirfenidone (n=107) between 2017 and 2023. Demographic, clinical, and radiological data were collected. Mortality predictors were analyzed using multivariate Cox regression, and survival outcomes were compared using adjusted Kaplan-Meier curves.

Results: Independent predictors of mortality were found to be six-minute walk distance (HR=0.99, 95% CI: 0.996–0.999, p=0.049), pulmonary fibrosis score ≥150 (HR=1.86, 95% CI: 1.07–3.22, p=0.026), and heart failure (HR=2.24, 95% CI: 1.18–4.26, p=0.014). After adjusting for these factors, no significant differences in mortality were observed between the nintedanib and pirfenidone groups.

Conclusions: Nintedanib and pirfenidone showed comparable effectiveness in reducing mortality among advanced-stage IPF patients. Future clinical trials should include advanced-stage patients to better evaluate treatment efficacy in this population.

References

Raghu G Collard HR Egan JJ Martinez FJ Behr J Brown KK et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198: e44-e68.

Richeldi L du Bois RM Raghu G Azuma A Brown KK Costabel U et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.

King TE Jr Bradford WZ Castro-Bernardini S Fagan EA Glaspole I Glassberg MK et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92.

Richeldi L Kreuter M Selman M Crestani B Kirsten AM Wuyts WA et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax 2018; 73: 581-3.

Kim JS Murray S Yow E Anstrom KJ Kim HJ Flaherty KR et al. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. Chest 2024; 165: 1163-73.

Finnerty JP Ponnuswamy A Dutta P Abdelaziz A Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med 2021; 21: 411.

King TE Jr Bradford WZ Castro-Bernardini S Fagan EA Glaspole I Glassberg MK et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92.

Noble PW Albera C Bradford WZ Costabel U Glassberg MK Kardatzke D et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9.

Wuyts WA Kolb M Stowasser S Stansen W Huggins JT Raghu G. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50% of Predicted Value. Lung 2016; 194: 739-43.

Chung MP Park MS Oh IJ Lee HB Kim YW Park JS et al. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. Adv Ther 2020; 37: 2303-16.

Pastre J Barnett S Ksovreli I Taylor J Brown AW Shlobin OA et al. Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respir Res 2021; 22: 5.

Stanojevic S Kaminsky DA Miller MR Thompson B Aliverti A Barjaktarevic I et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022; 60: 2101499.

Holland AE Spruit MA Troosters T Puhan MA Pepin V Saey D et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44: 1428-46.

Ley B Ryerson CJ Vittinghoff E Ryu JH Tomassetti S Lee JS et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-91.

Kazerooni EA Austin JH Black WC Dyer DS Hazelton TR Leung AN et al. ACR-STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (Resolution 4). J Thorac Imaging 2014; 29: 310-6.

Oda K Ishimoto H Yatera K Naito K Ogoshi T Yamasaki K et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res 2014; 15: 10.

Chahal A Sharif R Watts J de Andrade J Luckhardt T Kim YI et al. Predicting Outcome in Idiopathic Pulmonary Fibrosis: Addition of Fibrotic Score at Thin-Section CT of the Chest to Gender, Age, and Physiology Score Improves the Prediction Model. Radiol Cardiothorac Imaging 2019; 1: e180029.

Kolb M Richeldi L Behr J Maher TM Tang W Stowasser S et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017; 72: 340-6.

Albera C Costabel U Fagan EA Glassberg MK Gorina E Lancaster L et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016; 48: 843-51.

Behr J Nathan SD Costabel U Albera C Wuyts WA Glassberg MK et al. Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies. Adv Ther 2023; 40: 3937-55.

Man RK Gogikar A Nanda A Janga LSN Sambe HG Yasir M et al. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review. Cureus 2024; 16: e54268.